



**meetings
in a box**

ROAD TO ASCO GI 2026



A cura di Annalice Gandini, Genova

GASTROESOPHAGEAL CANCER

PANCREATIC AND BILIARY CANCER

COLORECTAL CANCER

GASTROESOPHAGEAL CANCER

ILUSTRO Phase 2 trial (K. Shitara – LBA 284)

1L zolbetuximab + mFOLFOX6 + nivolumab in CLDN18.2+ locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

HERIZON-GEA 01 Phase 3 trial (E. Elimova – LBA 285)

1L zanidatamab + CT +/- tislelizumab in HER2+ locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

ChiCTR2200061306 Phase 2 trial (Q. Liu – Abs 291)

1L tegafur + oxali + anti-PD1 +/- CarT cell in metastatic gastric/GEJ adenocarcinoma.

PANCREATIC AND BILIARY CANCER

LIRAFUGRATINIB (A. Hollebecque – Abs 476)

Efficacy and safety lirafugratinib in FGFR-i naive CCA with FGFR2 fusions/rearrangements.

KEYNOTE-937 Phase 3 trial (S. Chan – Abs 477)

Adjuvant pembrolizumab in HCC after surgery or local ablation.

IKF-035/ABC-HCC Phase 3b trial (P. Galle – Abs 478)

Atezolizumab + bevacizumab vs TACE in intermediate-stage HCC.

CHECKMATE 9DW Phase 3 trial (P. Galle – LBA479)

1L nivolumab + ipilimumab vs lenvatinib/sorafenib in HCC: 4-year follow-up update.

COLORECTAL CANCER

BREAKWATER Phase 3 trial (S. Kopetz – Abs 13)

Primary analysis 1L encorafenib + cetuxumab + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer.

COMMIT Phase 3 trial (C. Rocha Lima – Abs 14)

1L atezo vs atezo + mFOLFOX6 + beva in dMMR/MSI metastatic colorectal cancer